Gender-related invasion differences associated with mRNA expression levels of melatonin membrane receptors in colorectal cancer

Molecular Carcinogenesis

Volumn 51, Issue 8, 2012, Pages 608-618

  León, Josefa ^a,b   Casado, Jorge ^a,b   Carazo, Ángel ^a,b   Sanjuán, Laura ^a,b   Maté, Ana ^a   Muñoz de Rueda, Paloma ^a,b   De la Cueva, Paloma ^c   Quiles, Rosa ^a,b   Ruíz, Sergio ^a   Ruíz Extremera, Ángela ^a,b   Salmerón, Javier ^a,b  

^a HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c Red de Bancos de Tumores de Andalucía RBTA   (Spain)

Author keywords

Androgen receptor; Colorectal cancer; Melatonin membrane receptor; Oestrogen receptor alpha; Oestrogen receptor beta

Indexed keywords

6 CHLOROMELATONIN; ANDROGEN RECEPTOR; CELL NUCLEUS RECEPTOR; CELL NUCLEUS RECEPTOR ALPHA; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; MELATONIN 1 RECEPTOR; MELATONIN 2 RECEPTOR; MESSENGER RNA; RAMELTEON; STEROID RECEPTOR; UNCLASSIFIED DRUG;

ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INCIDENCE; CANCER INHIBITION; CANCER INVASION; CANCER STAGING; COLON MUCOSA; COLORECTAL CANCER; FEMALE; GENDER; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECTUM MUCOSA; SEX DIFFERENCE;

AGED; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; COLORECTAL NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HT29 CELLS; HUMANS; IMMUNOBLOTTING; INDENES; MALE; MELATONIN; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; RECEPTOR, MELATONIN, MT1; RECEPTOR, MELATONIN, MT2; RECEPTORS, ANDROGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SEX FACTORS;

EID: 84863427309     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.20832     Document Type: Article

References (42)

1. Markowitz SD, Bertagnolli MM. Molecular origins of cancer: Molecular basis of colorectal cancer. N Engl J Med 2009; 361: 2449-2460.
2. Hegde SR, Sun W, Lynch JP. Systemic and targeted therapy for advanced colon cancer. Expert Rev Gastroenterol Hepatol 2008; 2: 135-149.
3. Jung B, Ahmad N. Melatonin in cancer management: Progress and promise. Cancer Res 2006; 66: 9789-9793.
4. Reppert SM, Weaver DR, Ebisawa T. Cloning and characterization of a mammalian melatonin receptor that mediates reproductive and circadian responses. Neuron 1994; 13: 1177-1185.
5. Reppert SM, Godson C, Mahle CD, Weaver DR, Slaugenhaupt SA, Gusella JF. Molecular characterization of a second melatonin receptor expressed in human retina and brain: The Mel1b melatonin receptor. Proc Natl Acad Sci USA 1995; 92: 8734-8738.
6. Dubocovich ML, Markowska M. Functional MT1 and MT2 melatonin receptors in mammals. Endocrine 2005; 27: 101-110.
7. Wiesenberg I, Missbach M, Kahlen JP, Schrader M, Carlberg C. Transcriptional activation of the nuclear receptor RZR alpha by the pineal gland hormone melatonin and identification of CGP 52608 as a synthetic ligand. Nucleic Acids Res 1995; 23: 327-333.
8. Reiter RJ, Paredes SD, Manchester LC, Tan DX. Reducing oxidative/nitrosative stress: A newly-discovered genre for melatonin. Crit Rev Biochem Mol Biol 2009; 44: 175-200.
9. Lee PP, Shiu SY, Chow PH, Pang SF. Regional and diurnal studies of melatonin and melatonin binding sites in the duck gastro-intestinal tract. Biol Signals 1995; 4: 212-224.
10. Bubenik GA. Gastrointestinal melatonin: Localization, function, and clinical relevance. Dig Dis Sci 2002; 47: 2336-2348.
11. 2[125I]iodomelatonin binding sites in the human colon. Endocr Res 1996; 22: 77-94.
12. Vician M, Zeman M, Herichová I, Juráni M, Blazícek P, Matis P. Melatonin content in plasma and large intestine of patients with colorectal carcinoma before and after surgery. J Pineal Res 1999; 27: 164-169.
13. Cos S, González A, Martínez-Campa C, Mediavilla MD, Alonso-González C, Sánchez-Barceló EJ. Melatonin as a selective estrogen enzyme modulator. Curr Cancer Drug Targets 2008; 8: 691-702.
14. Sainz RM, Mayo JC, Tan DX, León J, Manchester L, Reiter RJ. Melatonin reduces prostate cancer cell growth leading to neuroendocrine differentiation via a receptor and PKA independent mechanism. Prostate 2005; 63: 29-43.
15. Martín V, Herrera F, Carrera-Gonzalez P, et al. Intracellular signaling pathways involved in the cell growth inhibition of glioma cells by melatonin. Cancer Res 2006; 66: 1081-1088.
16. Winczyk K, Fuss-Chmielewska J, Lawnicka H, Pawlikowski M, Karasek M. Luzindole but not 4-phenyl-2-propionamidotetralin (4P-PDOT) diminishes the inhibitory effect of melatonin on murine Colon 38 cancer growth in vitro. Neuro Endocrinol Lett 2009; 30: 657-662.
17. Winczyk K, Pawlikowski M, Guerrero JM, Karasek M. Possible involvement of the nuclear RZR/ROR-alpha receptor in the antitumor action of melatonin on murine Colon 38 cancer. Tumor Biol 2002; 23: 298-302.
18. Karasek M, Carrillo-Vico A, Guerrero JM, Winczyk K, Pawlikowski M. Expression of melatonin MT(1) and MT(2) receptors, and ROR alpha(1) receptor in transplantable murine Colon 38 cancer. Neuro Endocrinol Lett 2002; 23: 55-60.
19. Winczyk K, Pawlikowski M, Lawnicka H, et al. Effects of melatonin and melatonin receptors ligand N-[(4-methoxy-1H-indol-2-yl)methyl]propanamide on murine Colon 38 cancer growth in vitro and in vivo. Neuro Endocrinol Lett 2002; 23: 50-54.
20. Farriol M, Venereo Y, Orta X, Castellanos JM, Segovia-Silvestre T. In vitro effects of melatonin on cell proliferation in a colon adenocarcinoma line. J Appl Toxicol 2000; 20: 21-24.
21. García-Navarro A, González-Puga C, Escames G, et al. Cellular mechanisms involved in the melatonin inhibition of HT-29 human colon cancer cell proliferation in culture. J Pineal Res 2007; 43: 195-205.
22. Anisimov VN, Popovich IG, Shtylik AV, Zabezhinski MA, Ben-Huh H, Gurevich P. Melatonin and colon carcinogenesis. III. Effect of melatonin on proliferative activity and apoptosis in colon mucosa and colon tumors induced by 1, 2-dimethylhydrazine in rats. Exp Toxicol Pathol 2000; 52: 71-76.
23. Tanaka T, Yasui Y, Tanaka M, Tanaka T, Oyama T, Rahman KM. Melatonin suppresses AOM/DSS-induced large bowel oncogenesis in rats. Chem Biol Interact 2009; 177: 128-136.
24. Brozek W, Kriwanek S, Bonner E, Peterlik M, Cross HS. Mutual associations between malignancy, age, gender, and subsite incidence of colorectal cancer. Anticancer Res 2009; 29: 3721-3726.
25. Fiorelli G, Picariello L, Martineti V, Tonelli F, Brandi ML. Estrogen synthesis in human colon cancer epithelial cells. J Steroid Biochem Mol Biol 1999; 71: 223-230.
26. Castagnetta L, Traina A, Campisi I, et al. Androgen receptor status in nontumoral and malignant human colorectal tissues. Ann N Y Acad Sci 2002; 963: 322-325.
27. Konstantinopoulos PA, Kominea A, Vandoros G, et al. Oestrogen receptor beta (ERbeta) is abundantly expressed in normal colonic mucosa, but declines in colon adenocarcinoma paralleling the tumor's dedifferentiation. Eur J Cancer 2003; 39: 1251-1258.
28. Cho NL, Javid SH, Carothers AM, Redston M, Bertagnolli MM. Estrogen receptors alpha and beta are inhibitory modifiers of Apc-dependent tumorigenesis in the proximal colon of Min/+ mice. Cancer Res 2007; 67: 2366-2372.
29. Marugo M, Aste H, Bernasconi D, et al. Cytosolic and nuclear androgen receptors in colorectal adenomas. Anticancer Res 1992; 12: 705-708.
30. Pandi-Perumal SR, Trakht I, Srinivasan V, et al. Physiological effects of melatonin: Role of melatonin receptors and signal transduction pathways. Prog Neurobiol 2008; 85: 335-353.
31. Clemens JW, Jarzynka MJ, Witt-Enderby PA. Down-regulation of mt1 melatonin receptors in rat ovary following estrogen exposure. Life Sci 2001; 69: 27-35.
32. Ahmad R, Haldar C. Melatonin and androgen receptor expression interplay modulates cell-mediated immunity in tropical rodent Funambulus pennanti: An in-vivo and in-vitro study. Scand J Immunol 2010; 71: 420-430.
33. Andersen CL, Jensen JL, Ørntoft TF. Normalization of real-time quantitative reverse transcription-PCR data: A model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. Cancer Res 2004; 64: 5245-5250.
34. González A, Martínez-Campa C, Mediavilla MD, et al. Effects of MT1 melatonin receptor overexpression on the aromatase-suppressive effect of melatonin in MCF-7 human breast cancer cells. Oncol Rep 2007; 17: 947-953.
35. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61: 759-767.
36. Lai L, Yuan L, Cheng Q, Dong C, Mao L, Hill SM. Alteration of the MT1 melatonin receptor gene and its expression in primary human breast tumors and breast cancer cell lines. Breast Cancer Res Treat 2009; 118: 293-305.
37. Toma CD, Svoboda M, Arrich F, Ekmekcioglu C, Assadian O, Thalhammer T. Expression of the melatonin receptor (MT) 1 in benign and malignant human bone tumors. J Pineal Res 2007; 43: 206-213.
38. Cardinali DP, Ladizesky MG, Boggio V, Cutrera RA, Mautalen C. Melatonin effects on bone: Experimental facts and clinical perspectives. J Pineal Res 2003; 34: 81-87.
39. Campbell-Thompson M, Lynch IJ, Bhardwaj B. Expression of estrogen receptor (ER) subtypes and ERbeta isoforms in colon cancer. Cancer Res 2001; 61: 632-640.
40. Nakamura E, Kozaki K, Tsuda H, et al. Frequent silencing of a putative tumor suppressor gene melatonin receptor 1 A (MTNR1A) in oral squamous-cell carcinoma. Cancer Sci 2008; 99: 1390-1400.
41. Nojima D, Li LC, Dharia A, et al. CpG hypermethylation of the promoter region inactivates the estrogen receptor-beta gene in patients with prostate carcinoma. Cancer 2001; 92: 2076-2083.
42. Zhu X, Leav I, Leung Y, et al. Dynamic regulation of estrogen receptor-beta expression by DNA methylation during prostate cancer development and metastasis. Am J Pathol 2004; 164: 2003-2012.